Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older: Complete Statistical AnalysisIndependent statistical analysis of Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008): Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate: Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00319228).
- Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients: Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02927366).
- Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB): Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411: Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04101357).
- Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease): Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV): Complete Statistical AnalysisIndependent statistical analysis of Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza: Complete Statistical AnalysisIndependent statistical analysis of Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix: Complete Statistical AnalysisIndependent statistical analysis of Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix:…
- Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029): primary endpoint results, effect estimate with…
- Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants.: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04488770).
- Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects: primary…
- Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03383614).
- Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Tolerability and Preliminary Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeat Oral Doses of GSK3008356 in Healthy and Obese Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Preliminary Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeat Oral Doses of GSK3008356 in Healthy and Obese Subjects: primary endpoint results, effect estimate with…
- Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Tolerability, and Biosignature of Humanized Prebiotics in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Biosignature of Humanized Prebiotics in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06068894).
- Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19: primary endpoint results, effect estimate with confidence…
- Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03056001).
- Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002): primary endpoint results, effect estimate with confidence…
- Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027): primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007): primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007): primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…